Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel

NCT ID: NCT03994406

Last Updated: 2023-03-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-06-27
• Study Completion Date: 2019-10-30

Brief Summary

This study compares contact lens comfortable wear duration, and signs and symptoms of contact lens discomfort, test versus control.

Detailed Description

The clinical hypothesis is that CLM2 topical gel applied dermally on the forehead twice daily will be more effective than placebo (a) in reducing or eliminating ocular discomfort associated with contact lens wear, (b) prolong hours of comfortable wear, (c) prolong total hours of contact lens wear, (d) improve ease of insertion and removal of contact lens, and ( c) reduces friction between cornea/lens and lens/eyelid, without use of artificial eye drops or gels. One mechanism supporting this hypothesis is preliminary evidence of increased meibum secretion following CLM2 topical gel application.

Conditions

Contact Lens Discomfort; Contact Lens-induced Corneal Disorder; Contact Lens Acute Red Eye; Contact Lens-induced Corneal Fluorescein Staining

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

CLM2 Topical Gel

CLM2 topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.

Group Type: EXPERIMENTAL

CLM2 topical gel

Intervention Type: DRUG

Active topical gel for forehead dermal application

Placebo Topical Gel

Placebo topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.

Group Type: PLACEBO_COMPARATOR

Placebo topical gel

Intervention Type: DRUG

Placebo topical gel for forehead dermal application

Interventions

CLM2 topical gel

Active topical gel for forehead dermal application

Intervention Type: DRUG

Placebo topical gel

Placebo topical gel for forehead dermal application

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female of any race ≥18 years of age at Visit 1 Screening.

2. Has provided verbal and written informed consent.

3. Be able and willing to follow instructions, including participation in all study assessments and visits.

4. Has been wearing soft contact lens in both eyes at least 2 days per week for at least a month.

5. Duration of comfortable lens wear daily is less than desired.

6. Suffers from at least two other symptoms while wearing lens with contact lens discomfort of grade 2 or higher:

1. Dryness.

2. Grittiness

3. Blurred vision

4. Itching

5. Conjunctival redness

6. Burning

7. Stinging.

8. Lens awareness

9. Use of artificial tears or gels two or more times a day during contact lens wear hours.

7. Berkeley Dry Eye Flow Chart (DEFC) score ≥3.

Exclusion Criteria

1. BCVA at baseline <20/40.

2. Wearing contact lens only in one eye.

3. Wearers of the following contact lenses: Extended wear, prosthetic, scleral, and intracorneal gas permeable.

4. Pregnant women or women of childbearing potential who are not using contraception.

5. Diagnosis of the following autoimmune diseases: Addison's disease, Grave's disease, Hashimoto's thyroiditis, lupus, and Sjogren's syndrome.

6. Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assessments, such dystrophies, infections, etc.

7. Has a condition or be in a situation that, the opinion of the investigator, that may interfere significantly with the subject's participation in the study. No active ocular condition or disease.

8. Has a known adverse reaction and/or sensitivity to either study drug or its components.

9. Unwilling to remove contact lens overnight.

10. Unwilling to attempt to wear contact lens seven (7) days a week during the study period.

11. Plan to change brand of contact lens during study period.

12. Unwilling to wear contact lens for at least 10 hours if comfort permits, or until discomfort requires removal of contact lens prior to 10 hours.

13. Unwilling to discontinue swimming with immersed head for the duration of the study.

14. Unwilling to withhold the use of artificial tears, gels, or wetting agents during periods when contact lens is worn during the study period.

15. Cannot withhold the following medications during the study period:

antihistamines, some diuretics, antidepressants, antipsychotics, Restasis, Xiidra, Accutane, glaucoma medications, other anti-cholinergics; as well as gabapentin.

16. Currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Glia, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Meng C. Lin, OD,PhD,FAAO

Role: PRINCIPAL_INVESTIGATOR

University of California, Berkeley

Locations

UC Berkeley Clinical Research Center

Berkeley, California, United States

Countries

United States

Other Identifiers

CLM-1

Identifier Type: -

Identifier Source: org_study_id